| ALL Participants | Case-crossover with Both Before and After HAART Initiation | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
 | Prevalence [95% CI] (%) | Incidence [95% CI] (cases/100 person-years) | Prevalence [95% CI] (%) | Incidence [95% CI] (cases/100 person-years) | ||||||
HPV Types | HIV- n = 146 | HIV+Before HAART n = 170 | HIV+After HAART n = 157 | HIV- n = 146 | HIV+Before HAART n = 170 | HIV+After HAART n = 157 | Before HAART n = 100 | After HAART n = 100 | Before HAART n = 100 | After HAART n = 100 |
Carcinogenic | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
HPV 16a, c | 6 (2-10) | 17 (11-22)*** | 10(5-14) | 6.83 (3.53-11.96) | 6.54 (3.38-11.45) | 6.67 (3.45-11.68) | 20 (12-28)§§ | 7 (2-12) | 4.12 (2.13-7.20) | 4.64 (2.40-8.12) |
HPV18a, c | 8 (3-12) | 8 (4-12) | 6(2-9) | 4.66 (2.41-8.15) | 6.27 (3.24-10.97) | 7.32 (3.78-12.81) | 10 (4-16) | 4 (0-8) | 8.49 (4.39-14.86) | 5.72 (2.96-10.02) |
HPV39a | 0.7 (0-2) | 4(1-7)* | 4 (1-8)# | 1.93 (0.99-3.37) | 3.00 (1.55-5.25) | 3.06 (1.58-5.36) | 7 (2-12) | 3 (0-6) | 4.73 (2.45-8.28) | 1.50 (0.78-2.63) |
HPV45a | 2 (0-6) | 5 (2-8) | 4 (1-8) | 3.92 (2.02-6.85) | 4.30 (2.23-7.53) | 4.66 (2.41-8.16) | 5 (1-9) | 5 (1-9) | 4.55 (2.35-7.97) | 3.91 (2.02-6.84) |
HPV51a | 3 (0-6) | 2 (0-5) | 3 (0-5) | 4.86 (2.51-8.51) | 4.67 (2.41-8.17) | 4.48 (2.31-7.83) | 1 (0-3) | 2 (0-5) | 4.42 (2.29-7.74) | 3.68 (1.90-6.45) |
HPV52a | 3 (0-5) | 10 (5-15) | 9 (4-13)# | 4.67 (2.41-8.17) | 5.02 (2.59-8.78) | 5.11 (2.64-8.95) | 12 (6-18)§ | 4 (0-8) | 7.26 (3.76-12.71) | 3.17 (1.64-5.55) |
HPV56a | 2 (0-4) | 8 (4-12)* | 4 (1-7) | 2.60 (1.34-4.56) | 5.44 (2.81-9.53) | 4.21 (2.18-7.37) | 8 (3-13)§ | 1 (0-3) | 7.14 (3.69-12.49) | 5.98 (3.09-10.47) |
HPV58a | 10 (5-14) | 16 (11-22) | 10 (5-15) | 7.36 (3.80-12.88) | 7.71 (3.99-13.49) | 7.04 (3.64-12.32) | 20 (12-28)§§§ | 6 (1-11) | 6.93 (3.58-12.13) | 5.93 (3.07-10.38) |
HPV67b | 0.7 (0-2) | 1 (0-2) | 1 (0-2) | 0.64* (0.33-1.13) | 3.75 (1.94-6.56) | 1.49 (0.77-2.61) | 1 (0-3) | 0 | 3.29 (1.70-5.75) | 1.46 (0.76-2.56) |
HPV26/69b | 2(0-4) | 1 (0-3) | 3 (0-6) | 2.62* (1.35-4.58) | 6.79 (3.51-11.88) | 3.43 (1.78-6.01) | 0 | 2 (0-5) | 6.60 (3.41-11.55) | 5.96 (3.08-10.42) |
HPV53/66b | 5 (2-9) | 12 (7-17)* | 18 (12-24)### | 9.83 (5.08-17.20) | 12.80 (6.62-22.39) | 17.05# (8.82-29.84) | 11 (5-17) | 12 (6-18) | 12.93 (6.68-22.62) | 19.49 (10.08-34.10) |
HPV68/70b | 5 (2-9) | 11 (5-15) | 13 (8-19)# | 7.91 (4.09-13.85) | 9.01 (4.66-15.77) | 11.30 (5.84-19.77) | 15 (8-22) | 12 (6-18) | 10.36 (5.35-18.12) | 12.18 (6.30-21.31) |
HPV31/33/35a | 8 (4-13) | 14 (8-19) | 10 (5-15) | 6.87 (3.55-12.03) | 7.52 (3.89-13.15) | 8.85 (4.58-15.49) | 13 (6-20) | 6 (1-11) | 6.34 (3.28-11.10) | 7.77 (4.02-13.59) |
Low Risk | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
HPV6/11/42/44c, d | 8 (4-13) | 14 (8-19) | 8 (4-13) | 5.30 (2.74-9.27) | 7.97 (4.12-13.95) | 8.76 (4.53-15.32) | 20 (12-28)§ | 8 (3-13) | 7.59 (3.93-13.29) | 8.41 (4.35-14.72) |
HPV54/40d | 3(0-5) | 3 (0-5) | 3 (0-6) | 5.89 (3.04-10.31) | 8.49 (4.39-14.85) | 8.01 (4.14-14.02) | 4 (0-8) | 1 (0-3) | 6.67 (3.45-11.68) | 11.11 (5.74-19.44) |
HPV13/32d | 0.7 (0-2) | 1 (0-2) | 3 (0-5) | 2.24 (1.16-3.92) | 4.59 (2.37-8.03) | 3.71 (1.92-6.50) | 1 (0-3) | 3 (0-6) | 2.20 (1.14-3.85) | 5.14 (2.66-8.99) |
HPV62/72d | 0.7 (0-2) | 1 (0-2) | 1 (0-3) | 1.60 (0.83-2.80) | 2.91 (1.51-5.10) | 5.18# (2.68-9.06) | 0 | 0 | 1.09§ (0.56-1.91) | 7.20 (3.72-12.60) |
HPV2/57d | 0 | 1 (0-2) | 0 | 0 | 0.83 (0.43-1.46) | 1.45# (0.75-2.55) | 1 (0-3) | 0 | 0 | 1.43 (0.74-2.50) |
HPV55d | 0 | 0 | 0 | 0.96 (0.50-1.68) | 1.66 (0.86-2.91) | 0.36 (0.19-0.64) | 0 | 0 | 0 | 0.71 (0.37-1.25) |